CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience.
“Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “His financial expertise and experience in organizational scaling will help advance our leading scientific capabilities and commercial performance, ultimately contributing to our mission of transforming patients’ lives.”
Throughout his career, Mr. Kellogg played a critical role at leading biopharmaceutical companies with responsibility for core financial functions, including investor relations, corporate strategy, business development and alliance management. He most recently served as EVP, Chief Corporate Strategy Officer and had previously served as EVP, Chief Financial Officer at Celgene Corporation where he was instrumental in the consistent, year-over-year delivery of strong operating results up through the Company’s acquisition in 2019 by Bristol Myers Squibb. Prior to Celgene, Mr. Kellogg held the position of Chief Financial Officer at Merck & Co., Biogen Inc., and Frito Lay International, a division of PepsiCo, Inc. Currently, Mr. Kellogg serves as a member of the Board of Directors of Idorsia Ltd.
“Alnylam has an impressive track-record and has shown tremendous promise in progressing RNAi therapeutics with the potential to truly impact human health,” said Peter Kellogg, “I’m excited to join Alnylam’s Board of Directors and bring my passion and experience to this Company as it continues to grow commercially and strives to reach more patients in need.”
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
